<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amikacin liposome (oral inhalation): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amikacin liposome (oral inhalation): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amikacin liposome (oral inhalation): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="119248" href="/d/html/119248.html" rel="external">see "Amikacin liposome (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F51959742"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of increased respiratory adverse reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amikacin oral inhalation has been associated with an increased risk of respiratory adverse reactions including, hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51965668"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arikayce</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51959737"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Aminoglycoside</li></ul></div>
<div class="block doa drugH1Div" id="F51992968"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>For dosing of amikacin injection formulation via nebulization, refer to Amikacin (Systemic) monograph.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="673c0ab7-6c2b-4ebd-9cfa-852e633d3839">
<i>Mycobacterium abscessus</i> pulmonary disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium abscessus</i> pulmonary disease (off-label use): </b>Suspension for inhalation: One vial (590 mg) via nebulizer once daily as part of an appropriate combination regimen during the continuation phase of treatment; consult an infectious diseases specialist for specific recommendations, including duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32628747','lexi-content-ref-34314673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32628747','lexi-content-ref-34314673'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1409c5b6-662c-460f-bebe-8be017fd696b">
<i>Mycobacterium avium</i> complex pulmonary disease, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Mycobacterium avium</b></i>
<b> complex pulmonary disease, refractory:</b> Suspension for inhalation: One vial (590 mg) via nebulizer once daily as part of an appropriate combination regimen; consult an infectious diseases specialist for specific recommendations, including duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32628747','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32628747','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51992970"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F51992971"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; does not undergo hepatic metabolism.</p></div>
<div class="block doe drugH1Div" id="F51992969"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51962376"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (13%), nausea (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (≤16%), voice disorder (48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤16%), musculoskeletal pain (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ototoxicity (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (29%), cough (40%), exacerbation of pulmonary symptoms (15%; including chronic obstructive pulmonary disease and bronchiectasis), hemoptysis (18%), upper respiratory system symptoms (18%; including oropharyngeal pain, pharyngeal edema, throat irritation, upper respiratory tract inflammation)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (3%), oral candidiasis (4%), vomiting (7%), xerostomia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (5%), balance impairment (1%), dizziness (6%), headache (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Neuromuscular symptoms (1%; including myasthenia, peripheral neuropathy)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (4%), change in bronchial secretions (6%), epistaxis (3%), hypersensitivity pneumonitis (3%), pneumonia (9%), pneumothorax (2%), respiratory failure (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Decreased exercise tolerance (1%), fever (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Genitourinary: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F51959740"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to aminoglycosides</p></div>
<div class="block war drugH1Div" id="F51992953"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects</b></i>
<i>
<b>:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis, have been reported. Carefully screen for previous hypersensitivity reactions to aminoglycosides prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, exertional dyspnea, prolonged expiration, throat tightness, wheezing) has been reported; manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemoptysis: Hemoptysis has been reported; manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity pneumonitis: Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction) has been reported; manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Nephrotoxicity has been reported with aminoglycosides; use with caution in patients with known or suspected renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular blockade: May cause neuromuscular blockade and aggravate muscle weakness. Neuromuscular blockade is reversible but may require treatment (eg, administration of calcium salts, mechanical respiratory assistance).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: Ototoxicity (including deafness, dizziness, presyncope, tinnitus, vertigo) has been reported. Use with caution in patients with known or suspected auditory or vestibular dysfunction; if ototoxicity occurs, manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns</b></i>
<i>
<b>:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis; patients with neuromuscular disorders were not studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disease: Exacerbation of underlying pulmonary disease (reported as chronic obstructive pulmonary disease, infective exacerbation of chronic obstructive pulmonary disease, infective exacerbation of bronchiectasis) has been reported; manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients with genomic variants in <i>MT-RNR1:</i> Carriers of certain variants in the <i>MT-RNR1</i> gene (eg, m.1555A&gt;G) may be at increased risk for aminoglycoside-induced ototoxicity, including potentially significant hearing loss that may be irreversible, even when serum levels are within the normal range.</p></div>
<div class="block foc drugH1Div" id="F51965669"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Inhalation, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arikayce: 590 mg/8.4 mL (8.4 mL)</p></div>
<div class="block geq drugH1Div" id="F51965667"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52042928"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Arikayce Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">590MG/8.4ML (per mL): $78.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F51992973"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Inhalation: To be inhaled using the Lamira Nebulizer System over 14 to 20 minutes. Vial should be at room temperature prior to use (if refrigerated, remove at least 45 minutes before use). Shake vial for at least 10 to 15 seconds (until contents appear uniform and well mixed) prior to opening. Refer to the manufacturer's labeling for detailed administration instructions using the nebulizer system. Patients instructed to also use a bronchodilator should administer the bronchodilator prior to using the nebulizer.</p></div>
<div class="block meg drugH1Div" id="F54249740"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Arikayce: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F207356s004lbl.pdf%23page%3D15&amp;token=glYGW9WW0WQpMfbd7i63fPNWYwy55ouZv05JvVRZJDjZLC58YewgqUA6K5xY%2F8bZhAO1jknY%2FY6sfiaQ3m8TvJ%2Blv%2FuNcHJW%2BaAWnGRx6poh18oYnTrj489E7mamRpVd&amp;TOPIC_ID=119166" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207356s004lbl.pdf#page=15</a></p></div>
<div class="block use drugH1Div" id="F51959739"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Mycobacterium avium</i> complex pulmonary disease, refractory:</b> Treatment of <i>Mycobacterium avium</i> complex (MAC) pulmonary disease in adults who have limited or no alternative treatment options, as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitation of use: Amikacin oral inhalation has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of amikacin is not recommended for patients with non-refractory MAC lung disease.</p></div>
<div class="block off-label drugH1Div" id="F58111365"><span class="drugH1">Use: Off-Label: Adult</span><p>Mycobacterium abscessus pulmonary disease</p></div>
<div class="block cyt drugH1Div" id="F52013281"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F52013278"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the nephrotoxic effect of Amikacin Liposome (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Amikacin Liposome (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mannitol (Systemic): Amikacin Liposome (Oral Inhalation) may enhance the nephrotoxic effect of Mannitol (Systemic). <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F51992950"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aminoglycosides may cause fetal harm if administered during pregnancy. Systemic absorption of amikacin following oral inhalation is expected to be low compared to intravenous administration; however, systemic exposure was associated with total irreversible bilateral congenital deafness in children whose mothers received a different aminoglycoside during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the Amikacin (Systemic) monograph for details.</p></div>
<div class="block brc drugH1Div" id="F51992952"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if amikacin is present in breast milk following oral inhalation.</p>
<p style="text-indent:-2em;margin-left:2em;">Amikacin is present in breast milk following injection (Matsuda 1984). Systemic absorption following oral inhalation is expected to be low compared to IV administration. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Inhaled antibiotics used for the treatment of cystic fibrosis are considered compatible with breastfeeding (Panchaud 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Also refer to the Amikacin (Systemic) monograph.</p></div>
<div class="block mop drugH1Div" id="F55670662"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function, especially in patients with underlying known or suspected renal dysfunction.</p></div>
<div class="block pha drugH1Div" id="F51992956"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits protein synthesis in susceptible bacteria by binding to 30S ribosomal subunits</p></div>
<div class="block phk drugH1Div" id="F51992963"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Variable</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≤10%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5.9 to 19.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (7.42% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521679"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arikayce</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Arikayce</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Liposzomas arikayce</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arikayce</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Arikayce liposomal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Arikayce (amikacin liposome) inhalation suspension [prescribing information]. Bridgewater, NJ: Insmed; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32628747">
<a name="32628747"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis</i>. 2020;71(4):e1-e36. doi:10.1093/cid/ciaa241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/32628747/pubmed" id="32628747" target="_blank">32628747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26666259">
<a name="26666259"></a>Floto RA, Olivier KN, Saiman L, et al; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71(suppl 1):i1-22. doi:10.1136/thoraxjnl-2015-207360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/26666259/pubmed" id="26666259" target="_blank">26666259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34314673">
<a name="34314673"></a>Griffith DE, Daley CL. Treatment of mycobacterium abscessus pulmonary disease. <i>Chest</i>. 2022;161(1):64-75. doi:10.1016/j.chest.2021.07.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/34314673/pubmed" id="34314673" target="_blank">34314673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6743732">
<a name="6743732"></a>Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol.</i> 1984;5(2):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/6743732/pubmed" id="6743732" target="_blank">6743732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26942733">
<a name="26942733"></a>Panchaud A, Di Paolo ER, Koutsokera A, et al. Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients. <i>Respiration</i>. 2016;91(4):333-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amikacin-liposome-oral-inhalation-drug-information/abstract-text/26942733/pubmed" id="26942733" target="_blank">26942733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119166 Version 58.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
